Achromobacter xylosoxidans in cystic fibrosis:: Prevalence and clinical relevance

被引:117
作者
De Baets, Frans [1 ]
Schelstraete, Petra [1 ]
Van Daele, Sabine [1 ]
Haerynck, Filomeen [1 ]
Vaneechoutte, Mario [1 ]
机构
[1] State Univ Ghent Hosp, Cyst Fibrosis Ctr, B-9000 Ghent, Belgium
关键词
cystic fibrosis; Achromobacter xylosoxidans; Pseudomonas aeruginosa; lung function; morbidity;
D O I
10.1016/j.jcf.2006.05.011
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Achromobacter xylosoxidans is increasingly cultured in sputum from cystic fibrosis (CF) patients; nevertheless, there are few published data on the clinical impact of this infection or chronic colonisation. Methods: Relying on DNA fingerprinting techniques we studied the prevalence of A. xylosoxidans in our CF population. In a retrospective case control study the clinical status of patients with at least 3 sputum cultures positive for A. xylosoxidans over at least 9 months, at the moment of the first positive culture and during the period of colonisation were compared to age (1 year), gender and to Pseudomonas aeruginosa colonisation controlled CF patients who had never A. xylosoxidans positive sputum cultures. Results: The prevalence of patients with at least one positive A. xylosoxidans culture was 17.9%. 5.3% of the patients fulfilled the criteria of our definition of colonisation. Colonised patients had a median age of 20 years (range 11-27 years) and a mean colonisation period of 1.5 (+/- 0.9) years. At the moment of the first positive culture we found significantly lower Bhalla scores on HRCT scans of the lungs (11 +/- 3 versus 16 3, p<0.002), lower Brasfield chest X-ray scores (14 3 versus 18 3,p<0.019), lower FVC values (70% +/- 22 versus 94% +/- 12, p<0.017) and lower FEV1 values (55% +/- 32 versus 78% +/- 23,p = 0.123), although the latter did not reach significance. There was no significant difference 2 2 in body mass index (BMI) (18.7 +/- 3 kg/m(2) versus 19.6 +/- 3 kg/m(2), p=0.8). Over the study period A. xylosoxidans-colonised patients did have more need for intravenous antibiotic treatment courses (19 versus 5, p < 0.001); nevertheless, there was no significant difference in lung function decline over the study period (FVC: - 6.25 +/- 12.34% versus - 5.62 +/- 8.30%, p 0.77, FEV1: - 5.62 +/- 8.30% versus - 1.87 +/- 11.58%, p < 0.47). Conclusions: The prevalence of A. xylosoxidans infection or colonisation is probably underestimated. Colonised patients are mostly older, with more pronounced lung damage and lower lung function values. Although there was more need for intravenous antibiotic treatment courses, no faster decline in lung function was observed in A. xylosoxidans positive patients. (C) 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:75 / 78
页数:4
相关论文
共 16 条
[11]  
*US CF FDN, 1997, PAT REG
[12]  
*US CF FDN, 2002, PAT REG
[13]  
*US CF FDN, 1999, PAT REG
[14]  
*US CF FDN, 1995, PAT REG
[15]   Shared genotypes of achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center [J].
Van Daele, S ;
Verhelst, R ;
Claeys, G ;
Verschraegen, G ;
Franckx, H ;
Van Simaey, L ;
de Ganck, C ;
De Baets, F ;
Vaneechoutte, M .
JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (06) :2998-3002
[16]  
2002, BELGIAN CF REGISTER